Shasqi
Targeting Cancer with Click Chemistry
What they do
Systemic cancer therapies often cause dose-limiting toxicity because they expose the whole body to powerful drugs instead of concentrating treatment at tumors.
The CAPAC™ click-chemistry platform localizes a reagent at the tumor to activate a systemically delivered protodrug only at the tumor site for targeted therapy with reduced systemic exposure.
Oncologists and cancer treatment centers that administer therapeutic drugs to patients.
Founders
José M Mejía Oneto is a physician scientist with training in Organic Chemistry at Emory and Orthopedics at UC Davis. During his clinical training, Jose recognized the need for a better way to get drugs to the right location in the body. Joined the YC program in 2015 with Tambo and in 2018 its spinoff Shasqi, focussing on pioneering click chemistry in humans for better cancer drugs. Shasqi has raised a more than $60M in funding, with its lead asset in Phase 2 and a growing pipeline of drugs.
Company timeline
- Founded2015
- YC batchWinter 2015
- StatusActive
- Team size28 people
- LocationSan Francisco, CA, USA; Remote
Similar startups
